​Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 26, Sam Slutsky from LifeSci Capital reiterated a Buy rating on the stock and raised the price target from $39 to $45. Earlier, on January 14, Kelsey Goodwin from Piper Sandler reiterated a Buy rating on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) with a price target of $40. ​Analysts at Piper Sandler noted that the bullish rating is based on the company’s Palazestrant. Palazestrant is a pote ...

Company Overview - Olema aims to improve treatments for patients with ER-positive HER2-negative breast cancer, addressing significant unmet needs in this common cancer indication [1] Clinical Programs - Olema has two programs in the clinic: one in Phase III trials and one in Phase I/Phase Ib [2] - The lead asset, palazestrant, is a complete estrogen receptor antagonist, which is believed to be the best endocrine therapy for ER-positive HER2-negative breast cancer [2] Treatment Approach - Endocrine therapy is the backbone of treatment for ER-positive HER2-negative breast cancer, as the estrogen receptor is a primary driver of tumor growth and proliferation [3] - Palazestrant is currently in a first-line trial in combination with ribociclib, marking it as the only first-line trial of a CERAN/SERD in the endocrine-sensitive wild-type ESR1 setting [3] - Additionally, palazestrant is involved in a second third-line trial, OPERA-01, as a monotherapy [3]

Palazestrant (OP-1250) Development - Olema aims to establish Palazestrant as a best-in-class backbone therapy for ER+/HER2- breast cancer, both as a monotherapy and in combination with other anti-tumor agents[8] - The pivotal Phase 3 OPERA-01 clinical trial of Palazestrant as a monotherapy is ongoing, with top-line results expected in 2026[16, 37] - A pivotal Phase 3 OPERA-02 clinical trial of Palazestrant in combination with ribociclib is planned for initiation in 2025[3, 14, 16, 37, 88] - Palazestrant monotherapy Phase 2 data showed a median PFS of 73 months in 2/3L ±CT ESR1-mutant patients and 55 months in 2/3L ±CT ESR1-wild-type patients[45, 46, 47] - Palazestrant, at 120mg in combination with ribociclib, showed a 6-month PFS rate of 74% in all patients and 68% in patients with prior CDK4/6i[75, 80] OP-3136 (KAT6 Inhibitor) Development - Olema is advancing the clinical development of OP-3136, a potential best-in-class KAT6 inhibitor, in breast and other solid tumor cancers[10] - The FDA has cleared the Investigational New Drug (IND) application for OP-3136, and a Phase 1 clinical trial has been initiated[16, 100] - Preclinical data demonstrates that OP-3136 shows synergistic activity in combination with palazestrant[112] Market and Financial Position - The estimated global market for ER+/HER2- metastatic breast cancer is greater than $20 billion[35] - The U S market potential for Palazestrant in the 2/3L setting is estimated at $3-5 billion[63] - Olema has a strong capital position with $3927 million[13]